Iecure, Inc

iECURE is a clinical-stage genome editing company dedicated to transforming the lives of patients with devastating liver disorders by harnessing new advancements in genetic medicine. Our variant-agnostic, in vivo targeted gene insertion approach aims to restore the function of a missing or dysfunctional gene, regardless of variant, by inserting a functional copy to enable durable gene expression and the potential for long-term, curative benefit. We’re advancing a pipeline of genetic medicines, led by ECUR-506, an investigational therapy in clinical development for neonatal onset ornithine transcarbamylase (OTC) deficiency. Headquartered in Blue Bell, Pennsylvania, iECURE is proud to be recognized as one of the Philadelphia Business Journal’s “Best Places to Work” for two consecutive years and as one of Fierce Biotech’s “Fierce 15” in 2024.